Biblio Discovery — Demo Discovery Service

7 hasil untuk "Ian Proctor"

Menampilkan 1–7 · 0,58 detik · RSS

  1. Artikel Jurnal

    Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis

    Jahanzaib Khwaja; Encarl Uppal; Robert Baker dkk.

    eJHaem, Vol. 3 No. 4 · 2022 · Inggris · DOAJ

    Abstract Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. Management strategies have evolved with the introduction of targeted therapy including new classes of Bruton tyrosine kinase inhibitor (BTKi). Treatment may however be limited…

  2. Artikel Jurnal

    Biallelic deleterious germline SH2B3 variants cause a novel syndrome of myeloproliferation and multi‐organ autoimmunity

    Piers Blombery; Vahid Pazhakh; Adriana S. Albuquerque dkk.

    eJHaem, Vol. 4 No. 2 · 2023 · Inggris · DOAJ

    Abstract SH2B3 is a negative regulator of multiple cytokine receptor signalling pathways in haematopoietic tissue. To date, a single kindred has been described with germline biallelic loss‐of‐function SH2B3 variants characterized by early onset developmental delay, hepatosplenomegaly and autoimmune…

  3. Artikel Jurnal Teks lengkap

    Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

    Lewis Au; Emine Hatipoglu; Marc Robert de Massy dkk.

    Cancer Cell · 2021 · Inggris · OpenAlex Scopus

    T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode…

  4. Artikel Jurnal

    Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

    Kevin Litchfield; Stacey Stanislaw; Lavinia Spain dkk.

    Cell Reports, Vol. 31 No. 5 · 2020 · Inggris · DOAJ Scopus

    Summary: Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we…